# OMER catalysts: OMEROS CORP PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/omer/catalysts

> OMEROS CORP (OMER) has 2 upcoming catalysts. The next is the oms906 study drug primary completion, December 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only, half-year only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | OMEROS CORP |
| Ticker | OMER (Nasdaq) |
| SEC CIK | 1285819 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/omer |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| October 15, 2021 | [Yartemlea (narsoplimab-wuug) complete response letter (CRL)](https://sec-api.dev/pdufa/narsoplimab-wuug) | OMER |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761152_20211015.pdf%22)) |
| November 13, 2024 | [OMEROS CORP earnings report](https://sec-api.dev/companies/omer/catalysts) | OMER |  | completed | "Omeros Corporation Reports Third Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1285819/000143774924034900/ex_711279.htm)) |
| Dec 2024 | [Zaltenibart interim data readout](https://sec-api.dev/pdufa/zaltenibart) | OMER |  | scheduled | "Full details from interim analysis in the monotherapy portion of the trial will be presented at the annual meeting of the American Society of Hematology in December 2024." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1285819/000143774924034903/omer20240930_10q.htm)) |
| Mar 2025 | [YARTEMLEA® (narsoplimab) NDA/BLA submission](https://sec-api.dev/pdufa/narsoplimab) | OMER |  | completed | "In March 2025, we resubmitted to FDA the BLA seeking regulatory approval for narsoplimab in TA-TMA." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1285819/000143774925034826/omer20250930_10q.htm)) |
| March 31, 2025 | [OMEROS CORP earnings report](https://sec-api.dev/companies/omer/catalysts) | OMER |  | completed | "Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1285819/000143774925010211/ex_749944.htm)) |
| Q2 2025 | [YARTEMLEA® (narsoplimab) NDA/BLA submission](https://sec-api.dev/pdufa/narsoplimab) | OMER |  | scheduled | "Given the primary analysis results, we will resubmit the narsoplimab BLA for TA-TMA as quickly as possible followed by our planned submission of the corresponding European marketing authorisation application in the second quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1285819/000143774924037898/ex_755914.htm)) |
| May 6, 2025 | [YARTEMLEA® (narsoplimab) NDA/BLA acceptance](https://sec-api.dev/pdufa/narsoplimab) | OMER | hematopoietic stem cell transplant-associated thrombotic microangiopathy | completed | "On May 6, 2025, Omeros Corporation issued a press release announcing that the U.S. Food and Drug Administration accepted for review the resubmission of the Biologics License Application for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1285819/000143774925014815/omer20250506_8k.htm)) |
| May 12, 2025 | [OMEROS CORP earnings report](https://sec-api.dev/companies/omer/catalysts) | OMER |  | completed | "Omeros Corporation Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1285819/000143774925017211/ex_799147.htm)) |
| August 14, 2025 | [OMEROS CORP earnings report](https://sec-api.dev/companies/omer/catalysts) | OMER |  | completed | "Omeros Corporation Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1285819/000143774925026931/ex_822292.htm)) |
| late 2025 | [OMS527 interim data readout](https://sec-api.dev/pdufa/oms527) | OMER | with CUD | scheduled | "Work on the planned randomized, double-blind, parallel-group, inpatient Phase 1b clinical trial comparing the safety and efficacy of OMS527 to placebo in the treatment of adults with CUD is underway, and a preliminary data readout from that study is targeted by year-end 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1285819/000143774925010211/ex_749944.htm)) |
| late 2025 | [OMS527 topline data readout](https://sec-api.dev/pdufa/oms527) | OMER |  | scheduled | "Readout of preliminary data from that study is targeted by year-end 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1285819/000143774925010216/omer20241231_10k.htm)) |
| September 25, 2025 | [YARTEMLEA® (narsoplimab) PDUFA date](https://sec-api.dev/pdufa/narsoplimab) | OMER |  | scheduled | "Pursuant to the Prescription Drug User Fee Act ("PDUFA"), the class 2 resubmission was assigned September 25, 2025 as the target action date." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1285819/000143774925034824/ex_856792.htm)) |
| November 13, 2025 | [OMEROS CORP earnings report](https://sec-api.dev/companies/omer/catalysts) | OMER |  | completed | "Omeros Corporation Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1285819/000143774925034824/ex_856792.htm)) |
| December 2025 | [Biological: narsoplimab primary completion](https://sec-api.dev/pdufa/biological-narsoplimab) | OMER | Thrombotic Microangiopathies; Hematopoietic Stem Cell Transplantation | delayed | "NCT05855083 (Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2025-12 (ESTIMATED); Lead Sponsor Omeros Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05855083)) |
| December 23, 2025 | [Yartemlea (narsoplimab-wuug) FDA approval](https://sec-api.dev/pdufa/narsoplimab-wuug) | OMER | To treat hematopoietic stem cell transplant-associated thrombotic microangiopathy | completed, approved | "Yartemlea \| narsoplimab-wuug \| 12/23/2025 \| To treat hematopoietic stem cell transplant-associated thrombotic microangiopathyDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)) |
| December 24, 2025 | [YARTEMLEA® (narsoplimab) FDA approval](https://sec-api.dev/pdufa/narsoplimab) | OMER | hematopoietic stem cell transplant-associated thrombotic microangiopathy | completed, approved | "On December 24, 2025, Omeros Corporation (the "Company" or "we") issued a press release announcing that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA® (narsoplimab-wuug) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), an often-fatal complication of stem-cell transplantation driven by activation of the lectin pathway of complement." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1285819/000143774925038758/omer20251218_8k.htm)) |
| December 26, 2025 | [YARTEMLEA® (narsoplimab) PDUFA date](https://sec-api.dev/pdufa/narsoplimab) | OMER |  | completed, approved | "Following a comprehensive response to an FDA information request, the Agency extended the PDUFA date to December 26, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1285819/000143774925034824/ex_856792.htm)) |
| December 26, 2025 | [OMEROS CORP PDUFA date](https://sec-api.dev/companies/omer/catalysts) | OMER |  | scheduled | "Following the submission of information in response to an information request from FDA, FDA informed the Company that the PDUFA date will be extended to December 26, 2025." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1285819/000110465925070554/tm2516030d4_8k.htm)) |
| 2026 | [Zaltenibart topline data readout](https://sec-api.dev/pdufa/zaltenibart) | OMER |  | scheduled | "Zaltenibart's compelling results in our Phase 2 PNH trials are highly predictive of the similarly designed and ongoing Phase 3 program in PNH, which remains on track to readout data late next year, and we are focused on establishing ex-U.S. partnerships for both zaltenibart and narsoplimab." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1285819/000143774925010211/ex_749944.htm)) |
| March 31, 2026 | [OMEROS CORP earnings report](https://sec-api.dev/companies/omer/catalysts) | OMER |  | completed | "Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1285819/000143774926010634/ex_889301.htm)) |
| April 14, 2026 | [Oms906 study drug primary completion](https://sec-api.dev/pdufa/oms906-study-drug) | OMER | C3 Glomerulopathy; Idiopathic Immune Complex-Mediated Glomerulonephritis | withdrawn | "NCT06209736 (Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-04-14 (ACTUAL); Lead Sponsor Omeros Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06209736)) |
| May 13, 2026 | [OMEROS CORP earnings report](https://sec-api.dev/companies/omer/catalysts) | OMER |  | completed | "Omeros Corporation Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1285819/000143774926016718/ex_941648.htm)) |
| August 12, 2026 | [OMEROS CORP earnings report](https://sec-api.dev/companies/omer/catalysts) | OMER |  | completed | "Omeros Corporation Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1285819/000143774926027313/ex_966798.htm)) |
| December 2026 | [Oms906 study drug primary completion](https://sec-api.dev/pdufa/oms906-study-drug) | OMER | Paroxysmal Nocturnal Hemoglobinuria | scheduled | "NCT06298955 (Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Omeros Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06298955)) |
| Dec 2026 to Mar 2027 | [Oms906 study drug topline data readout](https://sec-api.dev/pdufa/oms906-study-drug) | OMER | Paroxysmal Nocturnal Hemoglobinuria | scheduled | "NCT06298955 (Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Omeros Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06298955)) |

## Drugs

- [Biological: narsoplimab](https://sec-api.dev/pdufa/biological-narsoplimab): Thrombotic Microangiopathies
- [YARTEMLEA® (narsoplimab)](https://sec-api.dev/pdufa/narsoplimab): hematopoietic stem cell transplant-associated thrombotic microangiopathy
- [Yartemlea (narsoplimab-wuug)](https://sec-api.dev/pdufa/narsoplimab-wuug): To treat hematopoietic stem cell transplant-associated thrombotic microangiopathy
- [OMS527](https://sec-api.dev/pdufa/oms527): with cud
- [Oms906 study drug](https://sec-api.dev/pdufa/oms906-study-drug): C3 Glomerulopathy, Paroxysmal Nocturnal Hemoglobinuria
- [Zaltenibart](https://sec-api.dev/pdufa/zaltenibart): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/omer/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "OMER catalysts: OMEROS CORP PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/omer/catalysts

```bibtex
@misc{secapidev_companies_omer_catalysts_20261116,
  title        = {OMER catalysts: OMEROS CORP PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/omer/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_omer_catalysts_20261116","title":"OMER catalysts: OMEROS CORP PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/omer/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
